NantBioscience And University of Colorado To Collaborate On Development Of Novel Protein Cancer Fighting Drugs

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LOS ANGELES--(BUSINESS WIRE)--NantBioScience, a NantWorks company focused on the discovery and development of innovative treatments for diseases with high unmet medical need, announced today a research collaboration and an exclusive worldwide licensing agreement with the University of Colorado for the development and commercialization of anti-cancer agents designed to target the Ral protein, a cell signaling protein implicated in the growth and spread of cancer. Through this partnership, NantBioScience will receive the exclusive right to develop and commercialize therapeutic and diagnostic products relating to the research activities.

NantBioScience’s broad development program includes novel agents that are designed to stop growth and spread of tumors by interfering with cancer communication pathways. Although the Ral protein has been found to play a role in the most commonly activated signaling pathways across cancer types, including colon, lung and pancreatic cancers, it has not yet been successfully targeted for potential therapeutic intervention. NantBioScience’s partnership with the University of Colorado and the Comprehensive Cancer Center is focused on the development of clinical compounds designed to block the function of the Ral protein.

Help employers find you! Check out all the jobs and post your resume.

Back to news